Keywords: galapagos, 1st-half, loss, soars, first, half, belgian
Galapagos' 1st-half loss soars 204%
Article | 20 August 2007
Loss for the first half of 2007 at Belgian drug discovery firm Galapagos grew 203.6% to 16.7 million euros ($23.1 million), despite a 140% revenue ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
